Hematology Question 5 Instructor

A 75 year old male presents to his GP with a complaint of palpitations. An EKG reveals that he is in atrial fibrillation. He is on a thiazide for hypertension but no other medications. Based on his CHADS-2 score, he would be a candidate for anti-coagulation to prevent stroke. What options would be available for someone in his circumstance?

The approved medications in Canada for non-valvular atrial fibrillation include warfarin to achieve a target INR between 2-3 and dabigatran at a dose of 150 mg p.o. bid. The largest trial (RE-LY) comparing Dabigatran to Warfarin was a double blinded non-inferiority RCT comparing these two dosing strategies in over 18,000 patients. The median duration of follow-up was 2.0 years with the primary outcomes being stroke or systemic embolism. The rates of stroke and VTE were similar between both arms, however there was a statistically lower rater of major bleeding an hemorrhagic stroke.

Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139.

Subscribe to Pearls

Uncle Sam wants you to subscribe to Medical Pearls

Subscribe today! It’s always free, and you can easily unsubscribe at any time. We will never share your email address. Subscribe to...

Multiple Pearls
Cardiology Pearls
Endocrinology Pearls
Hematology Pearls
Nephrology Pearls
Rheumatology Pearls
Transplant Pearls
General Internal Medicine Pearls
Instructor Pearls

Subscribe to receive your pearls today—it's free!